Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC –

SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”). This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone. These data are being submitted for presentation at an upcoming medical meeting.

“With the ongoing accumulation of data from the JUPITER-02 trial, we are thrilled to observe toripalimab gain more ground for becoming the preferred treatment for advanced NPC,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi/TopAlliance Biosciences. “Compared to chemotherapy alone, a combination containing the immune checkpoint inhibitor, toripalimab, clearly has the potential to bring unprecedented changes to the extension of life in patients with NPC. We are looking forward to bringing this promising therapy to patients around the world.”

“In the pivotal JUPITER-02 trial, toripalimab has demonstrated a statistically significant and clinically meaningful overall survival benefit for patients with advanced NPC, an aggressive head and neck tumor with no current FDA-approved treatment options,” said Rosh Dias, M.D., Coherus’ Chief Medical Officer. “These mature overall survival data continue to demonstrate the benefit of toripalimab in the treatment of NPC patients, further building upon the data published in Nature Medicine and presented at the 2021 plenary session at the ASCO annual meeting, and clearly show that toripalimab has the potential to become the new standard-of-care for NPC patients, once approved. We look forward to sharing these data with the oncology community at an upcoming medical meeting.”

The FDA has granted Breakthrough Therapy designations and priority review for the toripalimab Biologics License Application (“BLA”) for use in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® (pegfilgrastim), and CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis® (ranibizumab), in the U.S., and expects to launch the FDA-approved Humira®(adalimumab) biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in mid-2023. In January 2023, Coherus agreed to enter into definitive agreements providing for the acquisition of exclusive U.S. commercial rights to an Eylea® (aflibercept) biosimilar, FYB203, and plans to file a BLA for FYB203 in 2023.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ ability to build its immuno-oncology franchise to achieve a leading market position; Coherus’ ability to generate cash; Coherus’ investment plans; Coherus’ expectations for the launch date of YUSIMRY™; Coherus’ expectations about entering into definitive agreements and closing on those agreements to acquire exclusive U.S. commercial rights to an Eylea® biosimilar; expectations about Coherus’ ability to file a BLA for an Eylea® biosimilar; Coherus’ expectations about toripalimab gaining approval and becoming the new standard-of-care for patients with NPC after approval. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus’ competitors; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus’ business, the need to schedule inspections in China and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk of Coherus’ execution of its change in strategy from a focus on biosimilars to a strategy using cash from its portfolio to fund an oncology franchise; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-Q for the quarter-ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022, including the section therein captioned “Risk Factors” and in other documents that Coherus files with the Securities and Exchange Commission.

UDENYCA®, CIMERLI®, and YUSIMRY™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800

Coherus Contact Information

Marek Ciszewski, SVP Investor Relations

Jodi Sievers, VP Corporate Communications

GlobeNewswire Distribution ID 8750054

Röhrl’s Porsche 911 Dakar equipped with the right tyres from the desert to the Alps in partnership with Pirelli

MILAN, Italy, Feb. 15, 2023 (GLOBE NEWSWIRE) — The right tyre makes all the difference. Veteran driver Walter Röhrl, who in his rallying career has won on the most diverse tracks, from mud to asphalt, from gravel to snow, knows this well. And now for his Porsche 911 Dakar he can count on tyres that are specific to the type of terrain: from the Scorpion All Terrain Plus, designed for the sand of the desert, to the P Zero Winter, put to the test in the snow of the Alps, changing tyres is the key. Just like forty years ago, Röhrl explains, when he won the Monte Carlo Rally thanks to a strategy that allowed him to get the better of his opponents who, unlike him, were equipped with four-wheel drive; in order to deal effectively with both icy and dry asphalt, Röhrl’s team was the only one to opt for a tyre change, switching from studded Pirelli tyres to Pirelli slicks.

This is the first time that a Porsche 911 Dakar – a reinterpretation of the classic coupé in an all-terrain key, designed to maximise its off-road capabilities – has been fitted with a Pirelli off-road tyre as original equipment. The Scorpion All Terrain Plus tyre is specifically designed to offer resistance and support on the most demanding terrain, adapted to give the Porsche 911 Dakar the versatility of an off-roader as well as the high performance that has always been a feature of the iconic sports car, with a special development process.

Pirelli’s R&D department used compounds capable of handling performance on both gravel and asphalt. In addition, the structure has been and optimised to improve the footprint on the ground. Compared to the traditional Scorpion All Terrain Plus, the new tyre for the Porsche 911 Dakar has a tread pattern that delivers competitive performance in the dry, both on the circuit and in the desert. All this is achieved without compromising on aspects that are fundamental for everyday use, such as stability, safety and comfort. For the outdoor testing of this tyre, Pirelli drove the 911 Dakar on all the main European proving grounds and on a variety of tracks representative of a wide range of conditions.

Pirelli and Stuttgart have a long-standing partnership, so much so that the Porsche 911 was the first car to receive a marked Pirelli tyre (in this case, with the ‘N’ symbol) in 1982. As a result, Pirelli’s ‘Perfect Fit’ strategy was born with Porsche, a strategy that involves the development, alongside the most prestigious car manufacturers, of tyres that are specifically tailored to the most high-performance cars.

For more information:

Press Office LaPresse ufficio.stampa@lapresse.it

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2e615cdf-af52-4b8b-b9cd-a9a5473058f9

GlobeNewswire Distribution ID 8750009

Xometry to Announce Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023

ROCKVILLE, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global online marketplace connecting enterprise buyers with suppliers of manufacturing services, today announced it will report its fourth quarter and full-year 2022 financial results before the market open on March 1, 2023.

Xometry will host its conference call and webcast to discuss the results at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on the same day. In addition to its press release announcing its fourth quarter 2022 financial results, Xometry will also provide an earnings presentation, which will be available on its investor website at investors.xometry.com.

Xometry, Inc. Fourth Quarter 2022 Earnings Presentation and Conference Call

The earnings webcast presentation will be archived within the Investor Relations section of Xometry’s website.

About Xometry

Xometry (NASDAQ: XMTR) powers the industries of today and tomorrow by connecting the people with big ideas to the manufacturers who can bring them to life. Xometry’s digital marketplace gives manufacturers the critical resources they need to grow their business while also making it easy for buyers at Fortune 1000 companies to tap into global manufacturing capacity and create locally resilient supply chains. Learn more at www.xometry.com or follow @xometry.

Investor Contacts
Shawn Milne
VP Investor Relations

Media Contact
Matthew Hutchison for Xometry

GlobeNewswire Distribution ID 8749688

GreySkies Service Assurance Software Platform Helps Orange Egypt Reduce Operational Costs

GreySkies provides end-to-end visibility for Orange Egypt’s fixed and mobile networks

Featured Image for Greyskies Inc.

Featured Image for Greyskies Inc.

SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) — Today GreySkies, a telecommunications service assurance software provider, announced the completion of the deployment of its market-leading platform at Orange Egypt, the world’s leading telecommunications operator, enabling the reduction of their service assurance operational costs by 76%. These results were achieved by consolidating many expensive assurance tools, and right sizing the associated resources in the process. Furthermore, the advanced GreySkies capabilities in Machine Learning and Automation will enable Orange Egypt to model their services and address service degradations before impacting customers.

Orange Egypt felt comfortable going with GreySkies’ leading Universal Service Assurance solutions based on its superior technical capabilities, compelling business value proposition and high ROI, and thus, becoming the unifying platform to manage the performance of all its network services and correlate them with their customers’ experience.

“With the ongoing network transformation that Orange is going through, it is critically important to have a cutting-edge service assurance platform to help us pivot successfully in an ever-changing market,” said Ayman Amiri, Orange Egypt Chief Technology Officer. “We couldn’t be happier to work with a proven company like GreySkies, and we look forward to continuing working with them to provide better service quality to our customers.”

Monther Muharram, Director of Mobile & Fixed Core said, “With the universal nature of the GreySkies Service Assurance platform, it allows us to have one pane of glass to quickly and comprehensively monitor all our services and the impact on our customers. We are thrilled with the results we have seen thus far and look forward to continuing to capitalize on that platform after seeing the true impact GreySkies has on reducing our service assurance operational costs.”

“It is a great privilege for us to work with Orange Egypt, the operator of the fastest network in Egypt, and to partner with them through their transformation initiatives positioning them for IOT and the multi-cloud. It is indisputable that service quality is a determining factor in customer retention and acquisition. By deploying the GreySkies technology, Orange Egypt can quickly identify and resolve network issues through automation and advanced machine learning analytics” said Ahmed Mokhtar, GreySkies Chief Executive Officer.

About GreySkies

GreySkies Inc. provides Service Assurance solutions to network service providers and large enterprises. The Universal Service Assurance platform allows an operator’s engineering, operations, and planning teams to efficiently manage today’s complex and ever-changing infrastructure, enabling visibility at every layer. From infrastructure monitoring and end-to-end service modeling to subscriber analytics and customer quality of experience metrics, GreySkies unifies it all in one pane of glass, with machine learning and automation to close the loop. The platform provides universal support for all vendors and all technologies within a service provider’s network, including Cloud, 5G and IOT.

For more information on the internet and on your mobile: www.greyskiesinc.comor follow us on Twitter: @greyskiesinc and LinkedIn: company/greyskies

About Orange

Orange is one of the world’s leading telecommunications operators with sales of 42.5 billion euros in 2021 and 136,500 employees worldwide at 30 Sept. 2022, including 75,000 employees in France. The Group has a total customer base of 286 million customers worldwide on 30 Sept. 2022, including 240 million mobile customers and 24 million fixed broadband customers. The Group is present in 26 countries. Orange is also a leading provider of global IT and telecommunication services to multinational companies under the brand Orange Business Services. In December 2019, the Group presented its “Engage 2025” strategic plan, which, guided by social and environmental accountability, aims to reinvent its operator model. While accelerating in growth areas and placing data and AI at the heart of its innovation model, the Group will be an attractive and responsible employer, adapted to emerging professions.

For more information on the internet and on your mobile: www.orange.comwww.orange-business.com and the Orange News app, or follow us on Twitter: @orangegrouppr.

Orange and any other Orange product or service names included in this material are trademarks of Orange or Orange Brand Services Limited.

Contact Information:
Ahmed Mokhtar

Andrew Miller
Marketing Manager

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.


GlobeNewswire Distribution ID 8749945

100 Days to Go Until Vivid Sydney Dazzles Again

Vivid Sydney

Vivid Sydney

SYDNEY, Feb. 15, 2023 (GLOBE NEWSWIRE) — The countdown to Vivid Sydney 2023 has officially begun, with today marking 100 days until the festival’s Lights On moment at 6 p.m. on Friday, 26 May (AEST).

Celebrating creativity, innovation and technology, Australia’s largest festival will dazzle and delight audiences for 23 days and nights across four pillars this year — Vivid Light, Vivid Music, Vivid Ideas and the brand-new Vivid Food.

Minister for Tourism Ben Franklin said Vivid Sydney was one of Australia’s best events and a vital economic driver for New South Wales (NSW) during the winter months.

“Vivid Sydney is NSW’s biggest annual event and makes a vital social and economic contribution to our state. From our creative industries to entertainment and hospitality venues, accommodation and retailers, it supports and creates jobs across the NSW economy,” Franklin said.

“Last year, Vivid Sydney was attended by over 2.5 million people and injected $119 million into the NSW economy. With international borders fully reopening, we’re anticipating this year’s festival to be our biggest and best yet.

“Vivid Sydney 2023 promises to be a significant driver for domestic and international visitors to travel to NSW and attend Australia’s brightest event and immerse themselves in our city.”

This year’s creative direction, “Vivid Sydney, Naturally,” has been inspired by our connection to the natural environment and will be brought to life via a kaleidoscope of colourful light projections and activations, plus free and ticketed events.

Vivid Sydney Festival Director Gill Minervini said this year’s festival would raise the bar even higher than past events with festival-firsts, world-firsts and once-in-a-lifetime experiences.

“We are proud to have curated an impressive collection of local and international artists and food creatives to provide Vivid Sydney audiences with new and exciting experiences,” Minervini said.

“We have expanded and evolved the festival further this year and have curated an amazing lineup for 2023. The festival offering includes some significant new and Vivid-first experiences, as well as Vivid Food to deliver world-class culinary talent, events and activations as part of the program.”

A preview into some of the Vivid Sydney 2023 highlights includes:

  • The Vivid Sydney Light Walk will return in 2023 with more than 49 light installations and 3D projections along the 8.5km illuminated walk.
  • The internationally acclaimed, multi-sensory experience of light, colour and sounds, Lightscape, will transform The Royal Botanic Garden Sydney for the first time at Vivid Sydney.
  • First Nations artist Maree Clarke’s Barerarerungar will be projected on the Museum of Contemporary Art.
  • Internationally renowned Jen Lewin’s The Last Ocean will enthral audiences following its 2022 debut at Burning Man.
  • Brand-new festival pillar Vivid Food will activate across venues in Sydney’s central business district, showcasing a variety of creativity, innovation and culinary experiences from pop-up restaurants to haute cuisine, celebrating the city’s vibrant and diverse food culture.

Vivid Sydney 2023 will illuminate and energise various locations throughout the city, including Circular Quay, The Rocks, Barangaroo, Darling Harbour, The Goods Line, Central Station and Sydney icons such as the Sydney Opera House, the Sydney Harbour Bridge, the Museum of Contemporary Art and more.

Vivid Sydney is proudly owned, managed and produced by Destination NSW, the NSW Government’s tourism and major events agency. The complete program for Vivid Sydney 2023 will be announced in mid-March. For more information and to keep updated on the program, visit vividsydney.com.


Lightscape, The Royal Botanic Garden Sydney

For the very first time, the internationally acclaimed multi-sensory experience of light, colour and sound, Lightscape, is coming to The Royal Botanic Garden Sydney as part of Vivid Sydney 2023. Lightscape is a timed-entry event and sells out across the world.

Tickets are available now: vividsydney.com/lightscape.

Barerarerungar, Maree Clarke, Museum of Contemporary Art   

Maree Clarke is a Yorta Yorta, Wamba Wamba, Mutti Mutti, Boonwurrung artist and designer. Barerarerungar means “Country” in Boonwurrung and will be projected on the Museum of Contemporary Art. The impressive, stunning projection will pay tribute to practices on Country while also creating a space for communal reflection at the heart of Vivid Sydney.

The Last Ocean, Jen Lewin, Stargazer Lawn, Barangaroo Reserve   

This massive, interactive, tessellated “ice sheet” is made of recycled ocean plastic that shifts colour and shape beneath your feet. The Last Ocean, which made its debut at Burning Man in 2022, will be the largest-ever installation at Vivid Sydney.

For more information and to keep updated about the program, go to vividsydney.com.

Contact Information:
Jenna Whyte
PR Manager

Related Images

Image 1: Vivid Sydney

Credit: Destination NSW

This content was issued through the press release distribution service at Newswire.com.


GlobeNewswire Distribution ID 8749601

IADO educating elite athletes about anti-doping

The Indonesia Anti-Doping Organization (IADO) has been conducting anti-doping education for elite athletes participating in international events, including the SEA Games XXXII/2023 in Phnom Penh, Cambodia, and Asian Games XIX/2023 in Hangzhou, China.

In a statement issued on Wednesday, IADO said that it held a coordination meeting with the Indonesian Olympics Committee (KOI/Indonesia NOC) here on Tuesday as a follow-up to a memorandum of understanding (MoU) inked on November 18, 2022.

Based on the meeting’s results, the two parties are working to ensure that athletes receive anti-doping education before participating in the 2023 SEA Games and the 2023 Asian Games.

This is being done in accordance with a request from the Olympic Council of Asia (OCA) and the Southeast Asia Regional Anti-Doping Organisation (SEARADO) to member countries.

IADO and Indonesia NOC have also agreed to evaluate whether athletes had ever doped or not.

“IADO will utilize one of NOC’s rooms to hold direct meetings gradually,” IADO’s statement said.

Earlier, anti-doping education was provided to pencak silat athletes at TMII Pencak Silat Studio here on February 9, 2023.

Twelve athletes participated in the activity, which aims to increase their awareness of a doping-free sport.

This is in line with the World Anti-Doping Agency’s vision to prioritize anti-doping education.

Based on the activity’s evaluation result, most of the participants said they were satisfied and agreed that anti-doping education is very important.

Source: Antara News

Eliezer deserves to be granted justice collaborator status: Judge

Defendant Richard Eliezer (Bharada E) deserved being given the justice collaborator status in the premeditated murder case of Brigadier Nofriansyah Yosua Hutabarat (Brigadier J), the judge stated during the South Jakarta District Court trial, Wednesday.

“(Owing to) his honesty, courage, and determination to uncover this case, he deserved to be granted the status of justice collaborator or a witness willing to cooperate,” judiciary panel member Alimin Ribut Sujono remarked.

Sujono explained that to be a justice collaborator, someone should not be the main actor in a case that is being tried.

In a trial, Sujono said that Eliezer was not the main actor although he was the one who executed the plan and shot Brigadier J.

“The defendant has a role in shooting the victim, Yosua. Meanwhile, witness Ferdy Sambo was the one who had the idea, was the mastermind, the planner as well as the shooter of Yosua,” he remarked.

He concluded that Eliezer was one of the perpetrators, albeit not the main actor.

The panel said that Eliezer also deserves to be granted the status of a justice collaborator since much evidence in this case had disappeared, was destroyed, removed, and replaced, and had even dragged several police officers to blur facts.

“Although it put the defendant in a very dangerous position and situation for his life as the defendant walked alone,” he remarked.

He said that Eliezer’s honesty had helped bring clarity to this case, so the judges handed down lower sentences than that for the four other defendants.

The South Jakarta District Court handed a sentence of one year and six months’ imprisonment to Eliezer, lower than the 12-year prison term demanded by public prosecutors in a trial held on Wednesday, January 18, 2023.

Meanwhile, Ferdy Sambo was given death sentence, while his wife was awarded a 20-year prison term after they were found guilty of the murder in separate trials on Monday.

Kuat Ma’ruf was sentenced to a 15-year prison term, while Ricky Rizal was given a 13-year prison sentence.

Source: Antara News

Judges objective in sentencing Bharada E: Mahfud MD

The South Jakarta District Court handed an objective verdict to defendant Richard Eliezer (Bharada E) in the case involving the premeditated murder of Brigadier Nofriansyah Yosua Hutabarat, also known as Brigadier J.

Coordinating Minister for Political, Legal, and Security Affairs, Mahfud MD, conveyed the remarks while speaking to reporters at the Parliament building in Jakarta on Wednesday.

“I think the panel of judges has been really objective amidst internal and public pressure,” the minister declared.

He said he believed that the sentencing of Eliezer has fulfilled the public’s sense of justice.

He further said he felt grateful and ecstatic over the verdict given by the judges. The judges have shown nationalism and integrity, he added.

“Therefore, we should congratulate (them). I don’t know, I do not take sides, but today, I feel grateful and happy that we have nationalist and integrated judges,” he remarked.

The South Jakarta District Court on Wednesday sentenced Eliezer to one year and six months in prison over the murder of Brigadier J.

Eliezer’s sentence was lighter than the 12-year prison term sought by the public prosecutor on January 18, 2023.

“Sentenced the defendant Richard Eliezer with imprisonment for one year and six months,” Chief Judge Wahyu Iman Santoso said during the trial at South Jakarta District Court.

Eliezer was legally and convincingly proven guilty of violating Article 340, subsidiary Article 338 juncto Article 55, paragraph (1) 1st of the Criminal Code, he added.

In arriving at their decision, the judges took aggravating and mitigating factors into account, and the incriminating aspect was that Eliezer’s close relationship with the victim was not valued.

“(In terms of) the mitigating factor, the defendant is a witness to the perpetrators, who cooperated,” judiciary panel member Alimin Ribut Sujono said.

Source: Antara News